Friday, April 25, 2014

Zacks ups GeneNews price target to $3

Zacks ups GeneNews price target to $3

March 6, 2014 by · Leave a Comment 

Tweet Zacks Investment Research has raised its price target for “outperform-rated” GeneNews (TSX:GEN) to $3 from $2, saying revenue growth will accelerated in 2014 and beyond from a recently formed U.S. joint venture, Innovative Diagnostic Laboratory (IDL). Shares of GeneNews closed at $1.09 on Wednesday. “Specifically, we estimate revenue from IDL will be $2.6-million [in […]

Verisante expands its sales and marketing team

Verisante expands its sales and marketing team

February 26, 2014 by · Leave a Comment 

http://www.youtube.com/watch?v=gV2Fglh4-94′]

Tweet Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has hired Jason Mangler as director of sales to guide the company’s worldwide sales and marketing strategy and also hired Kim Ellis as its sales representative for Western Canada. As director of sales, Mr. Mangler will supervise the company’s sales and marketing team to identify market opportunities and fulfill market […]

GeneNews provides IDL jv progress update, appoints director

GeneNews provides IDL jv progress update, appoints director

November 14, 2013 by · Leave a Comment 

Tweet In its Q3 results release, GeneNews (TSX:GEN) provided a progress update and announced the appointment of Floyd C. Dent to its Board. In a statement, executive chairman James Howard-Tripp said start-up operations at Innovative Diagnostic Laboratory’s (IDL) Richmond, VA lab, which were initiated in the third quarter, have gone smoothly. “Soon after successfully obtaining CLIA […]

CytRx awaiting soft tissue sarcoma data in December

CytRx awaiting soft tissue sarcoma data in December

October 15, 2013 by · Leave a Comment 

Tweet What if it were possible to deliver a broad range of potent cancer drugs more optimally, enhancing both their safety and efficacy? That’s the question CytRx (NASDAQ:CYTR) hopes to answer this December when it plans to report top-line Phase 2b data from a global clinical trial of its lead drug, aldoxorubicin, as a first-line […]

Zachs starts GeneNews at outperform

Zachs starts GeneNews at outperform

July 5, 2013 by · Leave a Comment 

Tweet Zachs Investment Research has initiated coverage of GeneNews (TSX:GEN) with an “outperform” rating and 12-month price target of $3.50, saying the company’s revenue will accelerate in coming years due to a focused marketing strategy and new product offerings. The stock closed at 77 cents on Thursday. “Based on the company’s strong fundamentals, we think […]

GeneNews in JV; to launch ColonSentry test throughout US

GeneNews in JV; to launch ColonSentry test throughout US

July 2, 2013 by · Leave a Comment 

http://www.youtube.com/watch?v=0mzb8_cDcEg’]

Tweet GeneNews (TSX:GEN) has formed a joint venture with two private American companies, Health Diagnostic Laboratory, and a sales organization with national capabilities,  to establish an accredited clinical laboratory called Innovative Diagnostic Laboratory (IDL). IDL will initially focus on the development and broader U.S. commercialization of ColonSentry, the world’s first blood test to assess an […]

Exact Sciences’ data disappoints analysts; highlights differences with GeneNews’ test

Exact Sciences’ data disappoints analysts; highlights differences with GeneNews’ test

April 18, 2013 by · Leave a Comment 

http://www.youtube.com/watch?v=AcbKNlrpKLU’]

Tweet Shares of Exact Sciences (NASDAQ:EXAS) plummeted as much as 30% on heavier than normal trading volumes today after the company released a preliminary analysis of its DeeP-C pivotal trial with its Cologuard colorectal cancer screening test.   The stock recovered somewhat later in the day, closing down $1.14 to $8.84. Exact Sciences’ test, which identifies abnormal […]

In conversation with Gailina Liew

In conversation with Gailina Liew

January 22, 2013 by · Leave a Comment 

http://www.youtube.com/watch?v=0mzb8_cDcEg’]

Tweet As president and COO of GeneNews (TSX:GEN), Gailina Liew established the initial intellectual property strategy and organizational infrastructure for the company over the past dozen years. More recently, she has led the commercialization effort for ColonSentry, a new patient friendly blood test to assess an individual’s current risk of having colorectal cancer. ColonSentry is […]

In conversation with Jeffrey Frelick

In conversation with Jeffrey Frelick

January 8, 2013 by · Leave a Comment 

Tweet Jeffrey Frelick’s road to Wall Street began as a laboratory technologist with Clinical Pathology Facility before he joined Becton Dickinson in 1991 as a sales representative and regional sales manager. He also has been a consultant with Boston Biomedical Consultants, where he provided strategic planning assistance and market research data and conducted due diligence […]

GeneNews’ ColonSentry test gains media visibility in Malaysia

GeneNews’ ColonSentry test gains media visibility in Malaysia

December 11, 2012 by · Leave a Comment 

Tweet An article in the New Strait Times of Malaysia about colorectal cancer has highlighted the benefits of ColonSentry, a blood-based molecular test developed by GeneNews (TSX:GEN) to determine an individual’s current risk for colorectal cancer. The article quotes Professor Datuk Dr Liew Choong Chin, founder and chairman of GeneNews Diagnostics Sdn Bhd, who discusses […]

Next Page »

Google+